Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy, with most patients facing an adverse clinical outcome. Aberrant Notch pathway activation has been implicated in the initiation and progression of PDAC, specifically the aggressive phenotype of the disease. We 
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most devastating human malignancies characterized by extensive local invasion, early systemic dissemination, and pronounced resistance to chemotherapy and radiotherapy (1) . Outcomes for patients with advanced PDAC remain poor with limited clinical benefits seen with currently available therapy. For example, gemcitabine (GEM) as a systemic agent in the treatment of advanced PDAC results in a median survival of less than 6 months. A recent Phase III trial of a combination regimen comprised of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as first-line therapy has been shown to significantly improve median survival compared to GEM alone in patients with advanced PDAC (2) . Nonetheless, the safety profile of FOLFIRINOX was less favorable than that of GEM, and many patients remain ineligible to receive FOLFIRINOX (3) . Despite these ongoing advances, the continued poor survival in advanced PDAC underscores the need for new systemic therapies.
Notch signaling is an evolutionarily conserved pathway that plays an important role in multiple cellular and developmental processes (4) . While the Notch pathway plays a pivotal role in normal cell development, aberrant Notch signaling pathway has been extensively linked to a range of human malignancies, rendering this pathway a compelling target for drug development (GSIs) as a tractable avenue for Notch antagonism against a number of cancers linked with increased pathway activity (7, 8) .
Several lines of preclinical evidence suggest that sustained activation of Notch signaling pathway contributes to the initiation and maintenance of PDAC (9) . For example, in primary PDAC tissues, as well as in non-invasive precursor lesions of adenocarcinoma, multiple pathway components, including Notch ligands, receptors and target genes are over-expressed, relative to normal pancreas (10) . In an autochthonous mouse model of PDAC, pharmacological Notch inhibition attenuates the development of intraductal precursor lesions and invasive cancer, implicating this pathway in tumor initiation (11) . Further, down-regulation of Notch receptors by RNA interference or exposure to GSI in established human pancreatic cancer cells results in reduced proliferative rates, increased apoptosis, decreased anchorage independent growth and deceased invasive properties, suggesting a role for Notch signaling in PDAC maintenance as well (11, 12) .
In this study, we assessed the effects of MRK-003, a potent and selective GSI (13, 14) , in preclinical models of PDAC. MRK-003 is the preclinical analog of MK-0752, a GSI that is currently in clinical development (15, 16) . We used a panel of human PDAC cell lines, as well as patient-derived PDAC xenografts, to determine whether pharmacological targeting of the Notch pathway using MRK-003 could curb tumor growth and potentiate GEM sensitivity. Herein, we also attempt to delineate a gene signature of responsiveness to Notch inhibition, which may aid in the selection of patient subsets more likely to benefit from this strategy in the clinic. 
Anchorage independent growth
Anchorage independent growth of cells was determined by soft agar assays in 6-well plates.
Briefly, cells were incubated in media containing 0.5% FBS with vehicle or MRK-003 (2 or 5μM). After incubation for 48 hours, the treated cells were recovered by media with 10% FBS for 24 hours. Thereafter, equal numbers of viable cells from each condition were quantified using a hemocytometer with trypan blue counterstain, and then plated for soft agar assays. A bottom layer of 1% agarose, a middle layer of 0.6% agarose including 10,000 cells and a top layer of medium only were applied into each well. After incubating the plates for 3 weeks, colonies were stained with crystal violet solution, visualized by trans-UV illumination and counted using the analysis software Quantity One (BioRad).
Stable over-expression of Notch 1 intracellular domain
Stable transfectants overexpressing the Notch 1 intracellular domain (N1ICD) was established in Pa03C cells, as previously described (12) . The stable transfectants were maintained in media supplemented with 600 µg/mL of G418. Mock vector was transfected as a control.
Overexpression of N1ICD compared with empty vector-transfected cells was confirmed by qRT-PCR (12) .
Protein extraction and western blotting
Both N1ICD stable transfected as well as empty vector-transfected Pa03C cells were cultured separately in tissue culture flasks. Cells were trypsinized and cell pellets were lysed using lysis buffer. Western blots were performed as previously described (21) . Membranes were incubated with primary antibodies against rabbit N1ICD (Val1744) and Hes-1 (Cell Signaling Technology, Inc. and Abcam respectively). Membranes were probed with secondary horseradish peroxidaseconjugated antibody (GE Healthcare) and bound antibodies were detected by SuperSignal West Pico/Femto chemiluminescent substrate (Thermo Scientific). Equal loading was verified with β-actin antibody.
Engraftment of ex vivo pre-treated PDAC cells in athymic mice
Male athymic nude mice (6-week-old, Harlan) were housed and maintained in accordance with the Institutional Animal Care and Use Committee and guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care International. PDAC cells were treated ex vivo with either vehicle or with MRK-003 (5µM) for 48 hours, followed by a recovery in full serum conditions for an additional 24 hours, prior to subcutaneous injection. Viable 5×10 
Notch -1 gene expression
RNA isolated from baseline (untreated) tumors of 30 individual patient derived pancreatic cancer xenografts were profiled using Affymetrix U133 Plus 2.0 gene arrays. Sample preparation and processing procedure was conducted as described in the Affymetrix GeneChip Expression Analysis Manual (Affymetrix, Inc.). Gene expression levels were converted to a rank based matrix and standardized for each microarray (23) .
Xenograft establishment and in vivo efficacy studies
Low-passage PDAC xenografts established at Johns Hopkins Hospital was used for the study (24). Nine independent patient-derived xenografts were selected for the in vivo efficacy study, 
Gene expression analysis
RNA isolated from the nine parental (untreated) PDAC xenografts were profiled using Affymetrix U133 Plus 2.0 gene arrays at least in duplicates. This gene array has ~54,000 probes comprising ~20,000 RefSeq genes. CEL files generated from the array were normalized using the robust multiarray average algorithm (26). Pearson correlation coefficients were calculated to identify genes that show significant correlation (P<0.01) with tumor growth inhibition upon drug treatment. Pathway and biological function analysis of gene sets was performed using Ingenuity Pathway Analysis (IPA, Ingenuity Pathway Analysis, Redwood City, CA), and overlap of gene sets with other publicly available gene signatures was examined using NextBio (NextBio, Cupertino, CA). Microarray raw data are available in GEO (Accession number GSE37645).
Statistical Analysis
All groups were studied in parallel and differences between groups were analyzed by ANOVA, as appropriate, and Bonferroni multiple comparison tests performed using GraphPad Prism. The difference between experimental groups were considered significant when the P-value was <0.05. Bar and line graphs show mean ± SEM, respectively if not otherwise indicated.
Results

MRK-003 treatment down-regulates the expression of Hes-1 in PDAC cells
To determine whether MRK-003 could modulate Notch target genes, we examined the 
MRK-003 pre-treatment inhibits anchorage independent growth
Anchorage independent growth in soft agar was significantly reduced upon exposure to MRK-003 in Capan-1 at both 2 and 5µM dosages (P<0.01), while significant inhibition in the other two "sensitive" lines (Pa03C and Pa14C) was observed at 5µM dosing ( Figure 2B ). In contrast, the remaining two PDAC lines -Pa16C and Pa29C -were resistant to MRK-003 at both 2 and 5µM dosages ( Figure 2C ), despite the down-regulation of Hes-1 transcripts observed previously, suggesting other Notch effectors were involved in this phenotype.
Enforced expression of N1ICD rescues in vitro effects of MRK-003
To twelve "core" signaling pathways that are abnormal in this neoplasm (19) . Notch pathway components are enriched in PDAC patients resistant to GEM treatment and other molecular targeted agents (24, 32). The overwhelming majority of PDACs harbor activating mutations of KRAS (19) , and sustained Notch-1 signaling was shown to be essential in maintaining the transformed phenotype of Ras-mutant cells (33) . These multiple lines of evidence strongly support the pharmacological targeting of Notch signaling in PDAC, particularly in combination with GEM.
MRK-003 is a potent and selective GSI (13, 14) , which is the preclinical analog of MK-0752, A recent report indicated that a combination of MRK-003 and GEM could induce intra-tumoral necrosis in KPC mouse model (38) . In light of this, we examined the histological sections from treated xenografts and find that stroma-rich xenografts (for example Panc374, Supplementary induced cellular stress (43) . The precise cellular mechanisms by which an NRF2-activation signature leads to sensitivity to MRK-033/GEM regimen remains to be determined; nonetheless, the in silico correlations generated with regards to various activation signatures (NFκB, BCR, and Nrf2) in PDAC and response to either single agent GSI or combination regimens should be testable hypotheses, as these agents are increasingly being evaluated in the clinic. 
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